# Cytek Biosciences, Inc.: overview

CTKB · Nasdaq · CIK 1831915 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ctkb.md) · [Financials](/companies/ctkb/financials.md) · [Filings](/companies/ctkb/filings.md) · [Insiders](/companies/ctkb/insiders.md)

Latest reported revenue: [$48.1m](/filings/0001628280-26-053496.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-053496).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [51.5](/filings/0001628280-25-049697.md) | [57.5 d](/filings/0001628280-26-012352.md) | [41.5](/filings/0001628280-26-032293.md) | [45.6](/filings/0001628280-26-053496.md) | [52.3](/filings/0001628280-25-049697.md) | [62.1 d](/filings/0001628280-26-012352.md) | [44.1](/filings/0001628280-26-032293.md) | [48.1](/filings/0001628280-26-053496.md) |
| Gross margin | % | [56.3%](/filings/0001628280-25-049697.md) | [58.5% d](/filings/0001628280-26-012352.md) | [48.6%](/filings/0001628280-26-032293.md) | [52.3%](/filings/0001628280-26-053496.md) | [52.7%](/filings/0001628280-25-049697.md) | [52.9% d](/filings/0001628280-26-012352.md) | [48.2%](/filings/0001628280-26-032293.md) | [58.9%](/filings/0001628280-26-053496.md) |
| Operating margin | % | [(8.2%)](/filings/0001628280-25-049697.md) | [5.2% d](/filings/0001628280-26-012352.md) | [(36.1%)](/filings/0001628280-26-032293.md) | [(23.3%)](/filings/0001628280-26-053496.md) | [(17.6%)](/filings/0001628280-25-049697.md) | [(9.0%) d](/filings/0001628280-26-012352.md) | [(41.8%)](/filings/0001628280-26-032293.md) | [(23.7%)](/filings/0001628280-26-053496.md) |
| Net margin | % | [1.8%](/filings/0001628280-25-049697.md) | [16.8% d](/filings/0001628280-26-012352.md) | [(27.5%)](/filings/0001628280-26-053496.md) | [(12.2%)](/filings/0001628280-26-053496.md) | [(10.5%)](/filings/0001628280-25-049697.md) | [(70.9%) d](/filings/0001628280-26-012352.md) | [(42.7%)](/filings/0001628280-26-053496.md) | [(25.3%)](/filings/0001628280-26-053496.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Free cash flow | $m | [12.2 d](/filings/0001628280-25-049697.md) | [1.1 d](/filings/0001628280-26-012352.md) | [(1.0)](/filings/0001628280-26-032293.md) | [(1.5) d](/filings/0001628280-26-053496.md) | [(4.6) d](/filings/0001628280-25-049697.md) | [(1.8) d](/filings/0001628280-26-012352.md) | [(4.9)](/filings/0001628280-26-032293.md) | [(0.8) d](/filings/0001628280-26-053496.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL not reported.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [128](/filings/0001628280-24-010933.md) | [164](/filings/0001628280-25-008780.md) | [193](/filings/0001628280-26-012352.md) | [200](/filings/0001628280-26-012352.md) | [201](/filings/0001628280-26-012352.md) |
| Gross margin | % | [61.9%](/filings/0001628280-24-010933.md) | [61.6%](/filings/0001628280-25-008780.md) | [56.7%](/filings/0001628280-26-012352.md) | [55.4%](/filings/0001628280-26-012352.md) | [51.8%](/filings/0001628280-26-012352.md) |
| Operating margin | % | [7.2%](/filings/0001628280-24-010933.md) | [(1.1%)](/filings/0001628280-25-008780.md) | [(14.4%)](/filings/0001628280-26-012352.md) | [(10.2%)](/filings/0001628280-26-012352.md) | [(20.0%)](/filings/0001628280-26-012352.md) |
| Net margin | % | [2.4%](/filings/0001628280-24-010933.md) | [1.5%](/filings/0001628280-25-008780.md) | [(6.3%)](/filings/0001628280-26-012352.md) | [(3.0%)](/filings/0001628280-26-012352.md) | [(33.0%)](/filings/0001628280-26-012352.md) |
| Diluted EPS | $ per share | [0.00](/filings/0001628280-24-010933.md) | [0.02](/filings/0001628280-24-010933.md) | [(0.09)](/filings/0001628280-24-010933.md) | not reported | not reported |
| Free cash flow | $m | [0.3](/filings/0001628280-24-010933.md) | [(22.0)](/filings/0001628280-25-008780.md) | [0.6](/filings/0001628280-26-012352.md) | [21.9](/filings/0001628280-26-012352.md) | [(8.8)](/filings/0001628280-26-012352.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ctkb/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $42.4m | 9,578,643 |  | Reduced −7,428,626 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $41.4m | 9,338,010 |  | Added +3,046,212 |
| [Boston Partners](/funds/1386060.md) | 2026-06-30 | $33.9m | 7,660,943 |  | Added +1,858,170 |
| [HHLR ADVISORS, LTD.](/funds/1762304.md) | 2026-06-30 | $29.5m | 6,657,030 |  | Unchanged |
| [Topline Capital Management, LLC](/funds/1792549.md) | 2026-06-30 | $27.8m | 6,283,450 |  | Reduced −781,031 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $21.9m | 4,939,597 |  | Added +176,693 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $13.6m | 3,059,573 |  | Added +225,618 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $11.6m | 2,616,257 |  | Reduced −47,072 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $11.4m | 2,566,121 |  | Reduced −1,557,627 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $9.6m | 2,167,515 |  | Reduced −177,220 |

## Recent filings

[All 458 filings](/companies/ctkb/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-29 | 16:06 ET | [8-K](/filings/0001193125-26-407330.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-407330 |
| 2026-08-24 | 06:01 ET | [8-K](/filings/0001193125-26-361705.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-361705 |
| 2026-08-05 | 17:06 ET | [10-Q](/filings/0001628280-26-053496.md) | Quarterly report, period 2026-06-30 | 0001628280-26-053496 |
| 2026-08-05 | 16:22 ET | [8-K](/filings/0001193125-26-335212.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335212 |
| 2026-07-15 | 16:15 ET | [8-K](/filings/0001193125-26-304789.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-304789 |
| 2026-06-25 | 16:32 ET | [8-K](/filings/0001193125-26-282871.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-282871 |
| 2026-06-16 | 16:06 ET | [8-K](/filings/0001193125-26-272582.md) | 5.07 Shareholder vote results | 0001193125-26-272582 |
| 2026-06-02 | 16:15 ET | [8-K](/filings/0001193125-26-253538.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-253538 |
| 2026-05-07 | 17:03 ET | [10-Q](/filings/0001628280-26-032293.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032293 |
| 2026-05-07 | 16:14 ET | [8-K](/filings/0001193125-26-211948.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211948 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012352.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5e58abc7-3e92-4a92-949b-cac3b913216e)

## About the filer

- CIK: 1831915
- Tickers: CTKB
- Exchange: Nasdaq
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.